Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
The heterogeneity and complex nature of Alzheimer's disease (AD) is attributed to several genetic risk factors and molecular culprits. The slow pace and increasing failure rate of conventional drug discovery has led to the exploration of complementary strategies based on repurposing approved drugs to treat AD. Drug repurposing (DR) is a cost-effective, low-risk, and efficient approach for identifying novel therapeutic candidates for AD treatment. Similarly, hybrid drug design through the integration of distinct pharmacophores from known or failed drugs and natural products is an interesting strategy to target the multifactorial nature of AD. In this Perspective, we discuss the potential of DR and highlight promising drug candidates that can be advanced for clinical trials, backed by a detailed discussion on their plausible mechanisms of action. Our article fosters research on the hidden potential of DR and hybrid drug design with the goal of unravelling new drugs and targets to tackle AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pioglitazone (30) is a PPARγ agonist widely used in the treatment of T2D.478”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [478]
Citations
Cites
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,635
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Research works printed but not linked: 5
- Samanta S., 2022, Alzheimer’s Disease: Recent Findings in Pathophysiology, Diagnostic and Therapeutic Modalities, 1
- 10.1039/c5cc05264e · DOI · Paper page
- 10.1021/acschemneuro.8b00033 · DOI · Paper page
- 10.1172/jci0215451 · doi:10.1172/jci0215451 · Paper page
- Wang S., 2016, J. Alzheimers Parkinsonism Dement., 1, 007
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Yan, C., Dai, J., Yao, Y., Fu, W., Tian, H., Zhu, W., & Guo, Z. (2023) · Nature Protocols · doi:10.1038/s41596-022-00789-1 · Cited by 100
Multipronged diagnostic and therapeutic strategies for Alzheimer's disease
Ramesh, M., & Govindaraju, T. (2022) · Chemical Science · doi:10.1039/d2sc03932j · Cited by 94
Self-citationPadhi, D., Baruah, P., Ramesh, M., Moorthy, H., & Govindaraju, T. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103119 · Cited by 48
“We rationally designed and synthesized hybrid molecules by strategically integrating the structural and functional features of GA and CDPs to enhance their multifunctional therapeutic properties [34].”
MethodSelf-citationShoukat, S., Zia, M. A., Uzair, M., Attia, K. A., Abushady, A. M., Fiaz, S., Ali, S., Yang, S. H., & Ali, G. M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21161 · Cited by 39
“Therefore, developing more potent and effective medicinal chemicals is necessary [12].”
Background
Metadata
- Authors
- Padhi, D., & Govindaraju, T.
- Affiliations
- Jawaharlal Nehru Centre for Advanced Scientific Research (IN)
- Corresponding author
- Govindaraju, Thimmaiah
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-05-13
- Volume
- 65
- Issue
- 10
- Pages
- 7088-7105
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4280528552
- Cited by
- 47
- References
- 143
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 17 · 2023: 13 · 2022: 3
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Science and Engineering Research Board (CRG/2020/004594)
- Department of Science and Technology, Ministry of Science and Technology (DST/SJF/CSA-02/2015-2016, IFCPAR/CEFIPRA-62T10-3)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- Alzheimer's disease, drug repurposing, hybrid drug design, mechanism of action, natural products, complex diseases, clinical trial candidates
- MeSH terms
- Alzheimer Disease, Humans, Drug Discovery, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease. https://app.cochat.ai/papers/10.1021/acs.jmedchem.2c00335
- The paper
- Padhi, D., & Govindaraju, T. (2022). Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c00335
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.